2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Sialyltransferase
  5. Sialyltransferase Inhibitor

Sialyltransferase Inhibitor

Sialyltransferase Inhibitors (5):

Cat. No. Product Name Effect Purity
  • HY-173496
    ST6GAL1-IN-1
    		Inhibitor 99.22%
    ST6GAL1-IN-1 is an orally active selective ST6GAL1 inhibitor (IC50 = 20 μM). ST6GAL1-IN-1 exhibits high antimetastatic potential, effectively inhibiting the migration of MDA-MB-231 cells at noncytotoxic concentrations. ST6GAL1-IN-1 can disrupt integrin sialylation in MDA-MB-231 cells. ST6GAL1-IN-1 inhibits tumor angiogenesis and cancer metastasis via the Integrin/VEGFR2-mediated signaling pathway. ST6GAL1-IN-1 effectively suppresses both tumor growth and cancer metastasis on the MDA-MB-231 xenograft model. ST6GAL1-IN-1 can be used for the study of Triple-negative breast cancer (TNBC).
  • HY-163548
    SPP-002
    		Inhibitor 98.0%
    SPP-002 is a ST6GAL1 inhibitor with a human IC50 of 16.7 μM. SPP-002 selectively inhibits N-glycan sialylation over O-glycan sialylation and binds strongly to the enzyme active site. SPP-002 suppresses expression of signaling proteins in the integrin/FAK/paxillin pathway. SPP-002 can be used for the research of triple negative breast cancer metastasis.
  • HY-179101
    IAN-15B
    		Inhibitor
    IAN-15B has high selectivity and potent ST6GAL1 inhibitors (IC50 = 3.3 μM). IAN-15B has significant anti migratory and anti angiogenic effects. IAN-15B can be used in the research of cancer such as breast cancer.
  • HY-172888
    SPP-037
    		Inhibitor
    SPP-037 is an orally active and selective inhibitor of ST6GAL1 (IC50 = 3.59 μM). SPP-037 inhibits integrin α2,6-sialylation and integrin-FAK-paxillin pathway. SPP-037 inhibits cancer cell proliferation, migration and exhibits antiangiogenic activity. SPP-037 has anti-tumor activity in MDA-MB-231 xenograft mouse model. SPP-037 can be used for the research of triple-negative breast cancer.
  • HY-P991369
    EBU-141
    		Inhibitor
    EBU-141 is a human monoclonal antibody (mAb) targeting CD75/ST6GAL1. EBU-141 can be used in B-cell lymphoma and multiple myeloma research.